Two years into a malaria vaccine pilot scheme, more than 650,000 children have been immunized across Kenya, Ghana and Malawi, the World Health Organization said Tuesday.
Global advisory bodies for immunization and malaria are expected to convene in October to review data on the vaccine and consider whether to recommend using it more widely.
The RTS,S vaccine is the only existing jab shown to reduce malaria in children. It acts against plasmodium falciparum—the most deadly malaria parasite globally and the most prevalent in Africa.
Progress against malaria has been stalling for a number of years.
The WHO’s World Malaria Report 2020 said progress against the mosquito-borne disease was plateauing, particularly in African countries bearing the brunt of cases and deaths.
The annual report, published in November, said that after steadily tumbling from 736,000 in 2000, the disease claimed an estimated 411,000 lives in 2018 and 409,000 in 2019.
Meanwhile in 2019 the global tally of malaria cases was estimated at 229 million—a figure that has been at the same level for the past four years.
Over 90 percent of malaria deaths occur in Africa, the majority—more than 265,000—in young children.
The WHO said clinical testing had demonstrated that the RTS,S vaccine, when given in four doses, prevented four in 10 cases of malaria, and three in 10 cases of life-threatening severe malaria, over a four-year period.
“Ghana, Kenya and Malawi show that existing childhood vaccination platforms can effectively deliver the malaria vaccine to children, some of whom have not been able to access an insecticide treated bed net or other malaria prevention measures,” said Kate O’Brien, the WHO’s immunization chief.
“This vaccine may be key to making malaria prevention more equitable, and to saving more lives.”
Kenya becomes third country to adopt world’s first malaria vaccine
© 2021 AFP
650,000 African children given malaria jab: WHO (2021, April 20)
retrieved 20 April 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022